| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 02/08/2006 | EP1119362B1 Use of tetracycline derivatives to enhance interleukin-10 production |
| 02/08/2006 | EP1112362B1 GENE MODIFICATION IN THE GENE FOR THE DIE G$g(b)3-SUB-UNIT OF HUMAN G-PROTEIN |
| 02/08/2006 | EP1039933B1 METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE AND FOR THE PRODUCTION OF $i(IN VITRO) MABS |
| 02/08/2006 | EP1032669B1 Recombinant allergen with reduced enzymatic activity |
| 02/08/2006 | EP0971587B1 Quinoline leukotriene antagonists |
| 02/08/2006 | EP0694067B1 T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| 02/08/2006 | CN1732147A Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 02/08/2006 | CN1731999A Benzothiazole derivatives |
| 02/08/2006 | CN1731988A Sustained release pharmaceutical composition |
| 02/08/2006 | CN1730479A Aloe dihydro-coumarin and its separation method and uses |
| 02/08/2006 | CN1730021A Medicine composition for treating cardiovascular and cerebrovascular diseases and preparing process thereof |
| 02/08/2006 | CN1729991A Dripping pills of tripterigium wilfordi glycosides and its preparation process |
| 02/08/2006 | CN1240846C Immunity stimulus amlose of bacterial strain from linteus and its application |
| 02/08/2006 | CN1240717C Low-toxicity human interferon-alpha analog |
| 02/08/2006 | CN1240706C Process for producing super critical extracting caterpillar fungus deoxynucleoside |
| 02/08/2006 | CN1240688C Quinazoline compounds |
| 02/08/2006 | CN1240684C Dibenzocycloheptene compound |
| 02/08/2006 | CN1240681C Nitrile derivatives as cathepsin K inhibitors |
| 02/08/2006 | CN1240437C Oral administered self-emulsifying formulations of pyranone proteinase inhibitors |
| 02/08/2006 | CN1240436C Synergistic action of ossification growth peptide and granule cell colony stimulating factor in hematopoiesis |
| 02/08/2006 | CN1240415C Tablets against allergic purpura |
| 02/08/2006 | CN1240403C Echinacea composition and method of manufacture |
| 02/08/2006 | CN1240392C Agent for promoting cell activation for external use |
| 02/08/2006 | CN1240390C Biologic converted ginseng composition and preparing process thereof |
| 02/08/2006 | CN1240323C Oxidation-inhibited biological nutritive healthy liquid and preparing method thereof |
| 02/07/2006 | US6995272 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide |
| 02/07/2006 | US6995238 Cyclopeptide derivatives |
| 02/07/2006 | US6995186 For therapy of allergic or inflammatory disorders of the eye and nose |
| 02/07/2006 | US6995184 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors |
| 02/07/2006 | US6995174 for inhibiting proteases |
| 02/07/2006 | US6994994 Of the tumor necrosis factor receptor family; given amino acid sequence; use treating diseases and disorders ameliorated or cured by decreasing the levels of ligands of the original CD40R such as autoimmune diseases |
| 02/07/2006 | US6994987 Process for producing tripeptides |
| 02/07/2006 | US6994977 Combining a compound to be tested, a host cell expressing a recombinant protein containing a mammalian C-C chemokine receptor 3 and a ligand for binding of ligand to such receptor, detecting the formation of a receptor-ligand complex |
| 02/07/2006 | US6994970 Peptides which bind auto-antibodies for use in extracorporeal treatment; peptides bound to solid support for chromatography; specified amino acid sequence |
| 02/07/2006 | US6994959 which compete with DNA-binding sites of regulatory proteins which regulate t-cell activity (CD28 and cytokines), preventing transcription; analyzing immunocompetence; for treatment of autoimmune diseases |
| 02/07/2006 | US6994863 Pharmaceutical and cosmetic carrier and composition for topical application |
| 02/07/2006 | US6994862 Comprising 9-90% by weight monoglyceride compound, 0.01-90% by weight emulsifier, 0-50% by weight water-insoluble material, 0-90.9% by weight of organic solvent; drug delivery |
| 02/07/2006 | US6994860 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
| 02/07/2006 | US6994857 A Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants) fused to albumin, is sufficient to prolong the shelf-lilfe of therapeutic protein |
| 02/07/2006 | US6994853 administering to a cancer patient in a time-staggered manner: autologous or allogeneic tumor cells of the same tumor type each treated to prevent their survival after reinfusion; and intact bispecific and/or trispecific antibodies |
| 02/07/2006 | US6994843 Delivery of stimulants through an inhalation route |
| 02/07/2006 | CA2340202C Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors |
| 02/07/2006 | CA2311344C 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability |
| 02/07/2006 | CA2026147C Cytotoxic agents comprising maytansinoids and their therapeutic use |
| 02/02/2006 | WO2006012508A2 Method of treating sjögren's syndrome |
| 02/02/2006 | WO2006012359A2 Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
| 02/02/2006 | WO2006011466A1 5-substituted-2-phenylamino-benzamide as mek inhibitor |
| 02/02/2006 | WO2002094990A3 Receptors and membrane-associated proteins |
| 02/02/2006 | US20060026700 Tissue specific genes and gene clusters |
| 02/02/2006 | US20060025597 4-(Aminomethyl)-2-(2,6-dioxo(3-piperidyl))isoindoline-1,3-dione hydrochloride; cytokines level reduced; tumor necrosis factor inhibitors; nontoxic; anticarcinogenic agents; antitumor agents (solid/blood-borne); cardiovascular disorders; osteoporosis; antiinflammatory agents; autoimmune diseases |
| 02/02/2006 | US20060025443 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate; serotonin receptor antagonist; antidepressant, anxiolytic agent; migraine and sleep apnoea; weight loss and hepatocyte changes |
| 02/02/2006 | US20060025432 N-[2-[(3-Chloro-2-fluorobenzyl)thio]-6-[(2-hydroxy-1-methylethyl)amino]-4-pyrimidinyl]- 4-morpholinesulfonamide; asthma, antiallergens; rhinitis, chronic obstructive pulmonary disease, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis |
| 02/02/2006 | US20060025428 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/02/2006 | US20060025423 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma |
| 02/02/2006 | US20060025413 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 02/02/2006 | US20060025410 2,4-Pyrimidinediamine compounds and their uses |
| 02/02/2006 | US20060025403 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 02/02/2006 | US20060025391 Combination of azelastine and steroids |
| 02/02/2006 | US20060025362 Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation |
| 02/02/2006 | US20060025356 28-epirapalogs |
| 02/02/2006 | US20060024795 Interferon-Like molecules and uses thereof |
| 02/02/2006 | US20060024792 G-protein coupled receptors |
| 02/02/2006 | US20060024683 Transcription factor of MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances |
| 02/02/2006 | US20060024373 Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants |
| 02/02/2006 | US20060024334 Immunotherapeutic methods and systems |
| 02/02/2006 | US20060024322 Novel prophylactics/remedies for immunopathy |
| 02/02/2006 | US20060024316 Prostatic cancer vaccine |
| 02/02/2006 | US20060024293 Antibody for use in the treatment and prevention of sepsis, infections, autoimmune and graft-versus-host diseases; biodegradable, biocompatible polymer and human antibody, or an antigen-binding portion thereof, that dissociates from human TNF alpha |
| 02/02/2006 | US20060024267 TNFr/OPG-like molecules and uses thereof |
| 02/02/2006 | DE202005017617U1 Ointment and/or gel composition, useful for preventing allergies due to chromate, comprises tin II-ions in a conventional protective ointment or a conventional protection gel based on fat |
| 02/02/2006 | DE19856463B4 Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren Retroviral pseudotyped with LCMV hybrid vectors |
| 02/02/2006 | DE102004034623A1 Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel New 6-formyl-tetrahydropteridines, processes for their preparation and their use as medicaments |
| 02/02/2006 | CA2575518A1 Medicinal composition as immunosuppressant |
| 02/02/2006 | CA2575356A1 Use of llt1 and/or cd161 for modulating the activity of cells of the immune system |
| 02/02/2006 | CA2575272A1 Use of k-252a and kinase inhibitors for the prevention or treatment of hmgb1-associated pathologies |
| 02/02/2006 | CA2575218A1 Recombinant vaccines against caligid copepods (sea lice) and antigen sequences thereof |
| 02/02/2006 | CA2574664A1 Compound formulations of 2-amino-1,3-propanediol compounds |
| 02/02/2006 | CA2574305A1 1, 1a, 5, 5a-tetrahydro-s-thia-cyclopropa'a! pentalenes: tricyclic thiophene derivatives as s1p1/edg1 receptor agonists |
| 02/02/2006 | CA2573359A1 Method of treating sjogren's syndrome |
| 02/02/2006 | CA2573018A1 Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
| 02/01/2006 | EP1621633A2 Glycoproteins produced in plants with suppressed expression of beta 1, 2-xylosyltransferase |
| 02/01/2006 | EP1621627A2 Use of porcine gala (1,3) galactosyl transferase in xenograft therapies |
| 02/01/2006 | EP1621616A1 Human antihuman interleukin-18 antibody, fragment thereof and method of using the same |
| 02/01/2006 | EP1621615A1 Method of purifying modified acarian main allergen |
| 02/01/2006 | EP1621554A1 Immunoglobulins devoid of light chains |
| 02/01/2006 | EP1621551A1 Use of LLT1 and/or CD161 for modulating the activity of cells of the immune system |
| 02/01/2006 | EP1621548A2 Polypeptides, CDNAs encoding the same and utilization thereof |
| 02/01/2006 | EP1621540A1 Nitrogen-containing heterocyclic compounds and use thereof |
| 02/01/2006 | EP1621219A2 Intraocular implants for preventing transplant rejection in the eye |
| 02/01/2006 | EP1621208A1 DNA vaccination for treatment of autoimmune disease |
| 02/01/2006 | EP1621199A1 Remedies for diseases to be applied to eye |
| 02/01/2006 | EP1621195A2 The use of pyridinic NK-1 receptor antagonists for the treatment of brain, spinal or nerve injury |
| 02/01/2006 | EP1620545A2 Disease prevention and vaccination following thymic reactivation |
| 02/01/2006 | EP1620402A1 Cyclic quaternary amino derivatives as modulators of chemokine receptors |
| 02/01/2006 | EP1620126A2 Disease prevention and vaccination prior to thymic reactivations |
| 02/01/2006 | EP1620125A2 Tolerance to graft following thymic reactivation |
| 02/01/2006 | EP1620119A2 Use of b7-h3 as an immunoregulatory agent |
| 02/01/2006 | EP1619952A2 Tolerance to graft prior to thymic regeneration |
| 02/01/2006 | EP1500654B1 Benzoxazinone derivatives, the preparation and use thereof as medicaments |
| 02/01/2006 | EP1466622A4 Medicinal agent and method for curing diseases accompanied with vascular dystonia |